CorMedix Inc. CRMD
5.37 USD +0.07 (+1.32%)
Nov 12, 2026, 10:02 AM EST
5.15 Day range 5.49
5.10 52-week range 13.02
- YTD
- -53.83%
- 1 year
- -52.98%
News
zacks.com CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates CorMedix (CRMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.57 per share a year ago.
benzinga.com Cormedix Q3 2026 Earnings Call Transcript Cormedix (NASDAQ:CRMD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Cormedix Q3 EPS $(0.19) Misses $(0.10) Estimate, Sales $54.519M Beat $53.227M Estimate Cormedix (NASDAQ:CRMD) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.10) by 90 percent. This is a 133.33 percent decrease over earnings of $0.57…
benzinga.com Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $337.061M Est Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $337.061 million estimate.
globenewswire.com Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA of $3.1 million ‒ ‒ Company…
benzinga.com RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $14 to $15.
zacks.com CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
marketbeat.com CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings CorMedix NASDAQ: CRMD has agreed to acquire substantially all of Heron Therapeutics' assets, adding four commercial products and a development agreement to its portfolio of medicines used in…
benzinga.com Needham Maintains Buy on Cormedix, Raises Price Target to $14 Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $12 to $14.
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix Therapeutics (NASDAQ:CRMD) on Monday said it will acquire substantially all assets and assume certain liabilities of Heron Therapeutics, Inc. (NASDAQ:HRTX) in an upfront transaction valued…
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix acquires Heron Therapeutics assets for $222.6 million upfront, adding four commercial hospital therapies to expand its acute care reach.- benzinga.com CorMedix To Acquire Heron Therapeutics Assets For $145M Cash, Stock, And Potential Earn-Out Payments Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million…
globenewswire.com CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145…
globenewswire.com CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026,…
benzinga.com Needham Maintains Buy on Cormedix, Lowers Price Target to $12 Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $15 to $12.
benzinga.com CorMedix Reaffirms FY26 Total Sales Guidance Of $325M-$345M; Anticipates That The DefenCath Add-On Will Decline Sequentially In Q2 2027, With A QoQ Increase In Q3 And/Or Q4 CorMedix announces unaudited cash and cash equivalents on hand as of September 30, 2026 of approximately $355 million. CorMedix reaffirms its August 2026 total revenue guidance of between $325…
benzinga.com CorMedix Therapeutics Says FDA Accepts sNDA Filing Seeking Approval Of REZZAYO For Prophylaxis Of Invasive Fungal Disease; PDUFA Target Action Date Set In Q1 2027 CorMedix Therapeutics (NASDAQ:CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO®…- benzinga.com Actinium Pharmaceuticals Appoints Dr. Matt David As CFO Dr. David brings more than two decades of experience across biopharmaceutical operating leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc.…
benzinga.com Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15 Oppenheimer analyst Les Sulewski initiates coverage on Cormedix (NASDAQ:CRMD) with a Outperform rating and announces Price Target of $15.
benzinga.com RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.
benzinga.com CorMedix Stock Jumps on Strong DefenCath Sales CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.
benzinga.com Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% after being acquired by Thoma Bravo and reporting strong Q2 results. Other top gainers include Omeros…
benzinga.com Full Transcript: Cormedix Q2 2026 Earnings Call On Thursday, Cormedix (NASDAQ:CRMD) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…- benzinga.com Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $334.089M Est Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $334.089 million estimate.
benzinga.com Frequency Electronics Posts Weak Q4 Results, Joins AST SpaceMobile And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session US stock futures mixed, Dow futures up 0.2%. Frequency Electronics (FEIM) shares down 8.3% after reporting Q4 losses. Other stocks also lower in pre-market.
benzinga.com RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $14 to $13.
benzinga.com Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock, Optimum Communications, Cronos, and others also drop.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com Earnings Scheduled For March 5, 2026
benzinga.com Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings 
benzinga.com Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday - benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com Top Stocks With Earnings This Week: Plug, Oklo, Circle And More Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.
benzinga.com Hedge Fund Elliott Management's Q2 Moves Include Positions Tied To S&P 500, Nasdaq, Nvidia (CORRECTED) Hedge fund Elliott Management revealed a Q2 portfolio reshuffle, adding new positions tied to major indexes and tech leaders like Nvidia while exiting several prior holdings.
benzinga.com Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.- benzinga.com Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Tesla, SpartanNash, Standard BioTools And Other Big Stocks Moving Higher On Monday - benzinga.com Earnings Scheduled For May 6, 2025
benzinga.com Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday - benzinga.com Earnings Scheduled For March 25, 2025
- benzinga.com Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
- benzinga.com Earnings Scheduled For March 12, 2024 Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 14, 2023 Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
- benzinga.com Earnings Scheduled For August 8, 2023 Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share on revenue of $1.48 billion.
- benzinga.com Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket Gainers Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday.